An integrated proteomic approach to identifying circulating biomarkers in high‐risk neuroblastoma and their potential in relapse monitoring

Purpose: Despite intensive treatment regimens, overall survival for high‐risk neuroblastoma (HRNB) is still poor. This is in part due to an inability to cure the disease once a patient has reached clinical relapse. Identifying plasma biomarkers of active disease may provide a way of relapse monitoring in HRNB.

[1]  D. Schadendorf,et al.  Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  V. Pistoia,et al.  Chemokines in neuroectodermal tumour progression and metastasis. , 2009, Seminars in cancer biology.

[3]  K. Matthay,et al.  Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  H. Hosoi,et al.  RASSF1A hypermethylation in pretreatment serum DNA of neuroblastoma patients: a prognostic marker , 2009, British Journal of Cancer.

[5]  K. Matsuoka,et al.  Prognostic significance of circulating tumor cells and bone marrow micrometastasis in advanced neuroblastoma. , 2008, Journal of pediatric surgery.

[6]  H. Russell,et al.  Interleukin-6 and Soluble Interleukin-6 Receptor Levels as Markers of Disease Extent and Prognosis in Neuroblastoma , 2008, Clinical Cancer Research.

[7]  D. Chia,et al.  Multiplexed immunobead-based assay for detection of oral cancer protein biomarkers in saliva. , 2008, Oral diseases.

[8]  T. Imamura,et al.  Circulating Methylated-DCR2 Gene in Serum as an Indicator of Prognosis and Therapeutic Efficacy in Patients with MYCN Nonamplified Neuroblastoma , 2008, Clinical Cancer Research.

[9]  J. Marks,et al.  Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer , 2008, Breast Cancer Research.

[10]  J. Sandoval,et al.  Serum protein profiling to identify high-risk neuroblastoma: preclinical relevance of blood-based biomarkers. , 2007, The Journal of surgical research.

[11]  Marc E. Rothenberg,et al.  Regulation of Carcinogenesis by IL-5 and CCL11: A Potential Role for Eosinophils in Tumor Immune Surveillance1 , 2007, The Journal of Immunology.

[12]  Daniel Hartmann,et al.  Identification of Potential Markers for the Detection of Pancreatic Cancer Through Comparative Serum Protein Expression Profiling , 2007, Pancreas.

[13]  Ryuzo Ueda,et al.  CCR4 as a novel molecular target for immunotherapy of cancer , 2006, Cancer science.

[14]  J. Murray,et al.  Identification of a plasma proteomic signature to distinguish pediatric osteosarcoma from benign osteochondroma , 2006, Proteomics.

[15]  F. Bertucci,et al.  Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy , 2006, Oncogene.

[16]  John Maris,et al.  Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor. , 2005, Cancer research.

[17]  A. Puisieux,et al.  Protein chip array profiling analysis of sera from neuroblastoma patients. , 2005, Cancer letters.

[18]  Victor G Zgoda,et al.  Ovarian cancer marker of 11.7 kDa detected by proteomics is a serum amyloid A1 , 2005, Proteomics.

[19]  P. Tam,et al.  Serological protein profiling of neuroblastoma by ProteinChip SELDI‐TOF technology , 2005, Journal of cellular biochemistry.

[20]  S. Flibotte,et al.  Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions. , 2005, Clinical chemistry.

[21]  H. Shimada,et al.  Bone marrow mesenchymal stem cells provide an alternate pathway of osteoclast activation and bone destruction by cancer cells. , 2005, Cancer research.

[22]  John M Maris,et al.  The biologic basis for neuroblastoma heterogeneity and risk stratification , 2005, Current opinion in pediatrics.

[23]  M. Okcu,et al.  CXCR4 expression in neuroblastoma primary tumors is associated with clinical presentation of bone and bone marrow metastases. , 2004, Journal of pediatric surgery.

[24]  R. Bast,et al.  Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer , 2004, Cancer Research.

[25]  S. Baruchel,et al.  Factors Influencing Survival in Children With Recurrent Neuroblastoma , 2004, Journal of pediatric hematology/oncology.

[26]  E. Petricoin,et al.  SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. , 2004, Current opinion in biotechnology.

[27]  M. Ferrari,et al.  Clinical proteomics: Written in blood , 2003, Nature.

[28]  A. Puisieux,et al.  Circulating MYCN DNA as a tumor-specific marker in neuroblastoma patients. , 2002, Cancer research.

[29]  L. Lau.  NEUROBLASTOMA: A Single Institution's Experience with 128 Children and an Evaluation of Clinical and Biological Prognostic Factors , 2002, Pediatric hematology and oncology.

[30]  D. Stram,et al.  Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  M. Brenner,et al.  Antitumor responses induced by transgenic expression of CD40 ligand. , 1997, Human gene therapy.

[32]  C. Fielding,et al.  Molecular physiology of reverse cholesterol transport. , 1995, Journal of lipid research.

[33]  S. Groshen,et al.  Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells. , 2009, Cancer research.

[34]  E. Malle,et al.  Serum amyloid A: An acute-phase protein involved in tumour pathogenesis , 2008, Cellular and Molecular Life Sciences.

[35]  M. Finegold,et al.  Principles and practice of pediatric oncology , 2006 .

[36]  E. Barksdale,et al.  Neuroblastoma-induced inhibition of dendritic cell IL-12 production via abrogation of CD40 expression. , 2005, Journal of pediatric surgery.

[37]  M. Radmacher,et al.  Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. , 2003, Journal of the National Cancer Institute.